The present invention relates to aqueous pharmaceutical formulations, methods for their production, and uses thereof. The aqueous pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound and water, with a pH from 5 to 6.5, preferably from about 5 to about 6, and a concentration of the optionally substituted dimethyltryptamine compound of about 10 mg/ml or greater as the freebase equivalent. These formulations can comprise an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less. Such formulations are surprisingly suitable both for intramuscular injection and nebulised inhalation, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.
The present invention relates to compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I') is also provided.
The present invention relates to inhalable formulations, and kits and methods suitable for the preparation of such inhalable formulations. The inhalable formulationscomprise a freebase of a deuterium-substituted dimethyltryptamine compound. The inhalable formulations also comprise a biocompatible excipient. Such formulations are suitable for inhalation and have uses in the treatment of psychiatric or neurological disorders. Deuterium-substituted dimethyltryptamine compounds may be metabolised more slowly than their protio analogues, allowing for a longer lasting therapeutic effect.
Provided herein are pharmaceutical formulations, methods for their production, and uses thereof. The pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound, a buffer, which is separate to the salt, and water. The formulations have pH values of from about 3.5 to about 6.5 and osmolalities of about 250 to about 350 mOsm/Kg. Such formulations are optionally suitable for injection, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.
N,NN,NN,NN,NN,N N,NN,NN,N-dimethyltryptamine. In particular the invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof; (I) wherein the ratio of deuterium:protium in the compound is greater than that found naturally in hydrogen; each R1 is independently selected from H and D; R2333; R3333; and each yH is independently selected from H and D. Methods of synthesising compounds of the present invention, and methods of use of such compositions in treating psychiatric or neurological disorders, such as major depressive disorder, are also provided.
The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, as well as compositions comprising such compounds. These compounds and compositions have uses in the treatment of psychiatric or neurological disorders. Compounds of formula I comprise at least one deuterium atom at the α- position and consequently have improved oral bioavailability relative to α-diprotic analogues. (l)
The present invention relates to the synthesis of compounds of formula III from compounds of formula I via compounds of formula II. The present invention also relates to particular compounds of formula III, or pharmaceutically acceptable salts thereof, obtainable by the method, as well as compositions comprising such compounds. These compounds and compositions have uses in the treatment of psychiatric or neurological disorders.
N,NN,NN,NN,NN,NN,NN,NN,NN,NN,NN,NN,N-dimethyltryptamine. Methods of synthesising compositions of the present invention, and methods of use of presently described compositions in treating psychiatric or psychocognitive disorders, such as major depressive disorder, are also provided.
The present invention describes a compound of Formula (I), or a pharmaceutically acceptable salt thereof; wherein n is 0, 1, 2, 3, 4 or 5, R1, R2, R4, R5, and R6144 alkyl, each R31433. Compounds of the present invention are neurologically active by virtue of modulation of the glutamatergic system, and find therapeutic applications in a range of diseases and conditions of the central nervous system. In particular, compounds of Formula (I) are useful for treating disorders selected from neurocognitive, neurodevelopmental, and neuropsychiatric disorders.
The present invention describes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in increasing one or more of executive function, perceptual function, learning ability, memory, and attention in a human; wherein n is 0, 1, 2, 3, 4 or 5, R1, R2, R4, R5, and R6144 alkyl, each R31433, X is selected from CR7and CHR7, R714144 alkyl), benzyl, O(C=O)-R8, O(C=O)O-R8, O(C=O)NR8R922R833R833R8wherein R814242461061010 heteroaryl, and R944 alkyl, wherein == is a double bond when X is CR7, or a single bond when X is CHR7. In particular, compounds of Formula (I) are useful for treating disorders selected from neurocognitive, neurodevelopmental, and neuropsychiatric disorders, and have specific applications in increasing motivation, and for decreasing apathy.
The present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein ≃ is selected from a single bond and a double bond, wherein ≃ is 1, 2 or 3, wherein R1, R2, R3, R4, R5, and R6144 alkyl, and wherein when ≃ is a single bond R7143233H, and when ≃ is a double bond R7144 alkyl.
A61P 25/00 - Drugs for disorders of the nervous system
C07C 225/20 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
C07C 229/48 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
This invention relates to high concentration solid oral dosage forms of a ketamine metabolite selected from 2R,6R-hydroxynorketamine, 2S,6S-hydroxynorketamine, R-5,6- dehydronorketamine and S-5,6-dehydronorketamine.
The present invention provides novel, stable, processable and pharmaceutically acceptable salt forms of 2R,6R-hydroxynorketamineor 2S,6S-hydroxynorketamine with high aqueous solubility.
The present invention provides conformationally stabilized analogues of the ketamine metabolites 6-hydroxyketamine and 6-hydroxynorketamine with applications in the treatment of depression disorders and anxiety disorders. In particular the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof; wherein R1 is H or C1-C4 alkyl; R2 is H or C1-C4 alkyl; R3 is H or C1-C4 alkyl; R4 is H or C1- C4 alkyl; R5 is H or C1-C4 alkyl; R5 is H or C1-C4 alkyl; and R6 represents 0, 1, 2, 3, 4 or 5 haloatoms each independently selected from F, C1, Br,I, wherein when R2 is H, preferably at least one of R3, R4 and R5 is not H.
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
This invention relates to solid oral dosage forms of 2R,6R-hydroxynorketamine or prodrugs thereof having Formula Ib, including any pharmaceutically acceptable salt of the foregoing, for use in a therapeutic method for the treatment of a depressive disorder in a patient.
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/417 - Imidazole-alkylamines, e.g. histamine, phentolamine
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/6615 - Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
patents